Does TOPOTECAN Cause Malignant neoplasm progression? 238 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 238 reports of Malignant neoplasm progression have been filed in association with TOPOTECAN (HYCAMTIN). This represents 6.7% of all adverse event reports for TOPOTECAN.
238
Reports of Malignant neoplasm progression with TOPOTECAN
6.7%
of all TOPOTECAN reports
61
Deaths
26
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TOPOTECAN?
Of the 238 reports, 61 (25.6%) resulted in death, 26 (10.9%) required hospitalization, and 13 (5.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOPOTECAN. However, 238 reports have been filed with the FAERS database.
What Other Side Effects Does TOPOTECAN Cause?
Febrile neutropenia (425)
Off label use (390)
Death (332)
Product use in unapproved indication (323)
Neutropenia (255)
Pyrexia (252)
Anaemia (242)
Drug ineffective (216)
Disease progression (207)
Thrombocytopenia (207)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TOPOTECAN Alternatives Have Lower Malignant neoplasm progression Risk?
TOPOTECAN vs TOPOTECAN\TOPOTECAN
TOPOTECAN vs TOPROL
TOPOTECAN vs TOREMIFENE
TOPOTECAN vs TORIPALIMAB
TOPOTECAN vs TORSEMIDE